amantadine has been researched along with Hallucination of Body Sensation in 26 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis." | 8.31 | Amantadine toxicity causing visual hallucinations. ( Barbara, JM; Pace, A, 2023) |
| "In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 7.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
| "Amantadine hydrochloride is a commonly prescribed drug with a narrow therapeutic-to-toxic range." | 5.28 | Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. ( Hughes, B; Pimentel, L, 1991) |
| "Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis." | 4.31 | Amantadine toxicity causing visual hallucinations. ( Barbara, JM; Pace, A, 2023) |
| "In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy." | 3.65 | Visual hallucinations and delirium during treatment with amantadine (Symmetrel). ( Postma, JU; Van Tilburg, W, 1975) |
| "Amantadine was reduced to 50mg daily for 4 days and then discontinued." | 2.72 | Amantadine Associated Myoclonus: Case Report and Review of the Literature. ( Lee, AJ; Poon, LH; Vuong, M; Zuzuarregui, JR, 2021) |
| "To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without symptomatic infections." | 1.40 | Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. ( Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K, 2014) |
| "We describe an artist who depicted her visual hallucinations experienced in the course of Parkinson's disease." | 1.32 | An artist's view of drug-induced hallucinosis. ( Ebersbach, G, 2003) |
| " This long range study demonstrates, through multiple varied dosing schedules, a trade off between the benefits and side effects of dopaminergic therapy, with implications for a larger brain injury population." | 1.30 | Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. ( Burke, DT; Calvanio, R; Fitzpatrick, M; Karli, DC; Kim, HJ; Lepak, P; Macneil, M; Pesez, K; Temple, D, 1999) |
| "Amantadine hydrochloride is a commonly prescribed drug with a narrow therapeutic-to-toxic range." | 1.28 | Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. ( Hughes, B; Pimentel, L, 1991) |
| "Amantadine is an antiviral agent that is also used in the treatment of parkinsonism and neuroleptic-induced extrapyramidal symptoms." | 1.28 | Acute psychosis after amantadine overdose. ( Bessen, HA; Snoey, ER, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (38.46) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Barbara, JM | 1 |
| Pace, A | 1 |
| Pajo, AT | 1 |
| Espiritu, AI | 1 |
| Jamora, RDG | 1 |
| Poon, LH | 1 |
| Lee, AJ | 1 |
| Vuong, M | 1 |
| Zuzuarregui, JR | 1 |
| Sawada, H | 1 |
| Oeda, T | 1 |
| Umemura, A | 1 |
| Tomita, S | 1 |
| Hayashi, R | 1 |
| Kohsaka, M | 1 |
| Yamamoto, K | 1 |
| Sudoh, S | 1 |
| Sugiyama, H | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Moritoyo, T | 1 |
| Yabe, H | 1 |
| Nomoto, M | 1 |
| Michalski, LS | 1 |
| Hantsch Bardsley, C | 1 |
| Holt, DR | 1 |
| Milner, JE | 1 |
| Hou, SH | 1 |
| Gondim, Fde A | 1 |
| Costa, HA | 1 |
| Taunay, TC | 1 |
| de Oliveira, GR | 1 |
| Ferreira, JM | 1 |
| Rola, FH | 1 |
| Ebersbach, G | 1 |
| Kitagawa, M | 1 |
| Tashiro, K | 1 |
| Benbir, G | 1 |
| Ozekmekçi, S | 1 |
| Cinar, M | 1 |
| Beskardes, F | 1 |
| Apaydin, H | 1 |
| Erginöz, E | 1 |
| Visanji, NP | 1 |
| Gomez-Ramirez, J | 1 |
| Johnston, TH | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Brotchie, JM | 1 |
| Fox, SH | 1 |
| Ideshita, H | 1 |
| Morita, H | 1 |
| Yoshinaga, J | 1 |
| Sasaki, T | 1 |
| Hikiji, A | 1 |
| Dike, GL | 1 |
| Karli, DC | 1 |
| Burke, DT | 1 |
| Kim, HJ | 1 |
| Calvanio, R | 1 |
| Fitzpatrick, M | 1 |
| Temple, D | 1 |
| Macneil, M | 1 |
| Pesez, K | 1 |
| Lepak, P | 1 |
| Postma, JU | 1 |
| Van Tilburg, W | 1 |
| Strong, DK | 1 |
| Eisenstat, DD | 1 |
| Bryson, SM | 1 |
| Sitar, DS | 1 |
| Arbus, GS | 1 |
| Pimentel, L | 1 |
| Hughes, B | 1 |
| Snoey, ER | 1 |
| Bessen, HA | 1 |
| Gold, N | 1 |
| Penders, C | 1 |
| Forssman, B | 1 |
| Kihlstrand, S | 1 |
| Larsson, LE | 1 |
| Campbell, AM | 1 |
| Williams, MJ | 1 |
| Reveno, WS | 2 |
| Bauer, RB | 2 |
| Rosenbaum, H | 2 |
| Harper, RW | 1 |
| Knothe, BU | 1 |
| Holmsen, R | 1 |
2 reviews available for amantadine and Hallucination of Body Sensation
| Article | Year |
|---|---|
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Del | 2019 |
Amantadine Associated Myoclonus: Case Report and Review of the Literature.
Topics: Aged, 80 and over; Amantadine; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease | 2021 |
2 trials available for amantadine and Hallucination of Body Sensation
| Article | Year |
|---|---|
Amantadine therapy in parkinsonism.
Topics: Age Factors; Aged; Amantadine; Clinical Trials as Topic; Edema; Electrocardiography; Female; Follow- | 1972 |
Trial of amantadine in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Constipation; Female; Hallucinations; Handwriting | 1972 |
22 other studies available for amantadine and Hallucination of Body Sensation
| Article | Year |
|---|---|
Amantadine toxicity causing visual hallucinations.
Topics: Amantadine; Antiparkinson Agents; Female; Hallucinations; Humans; Levodopa; Multiple Sclerosis | 2023 |
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine A | 2014 |
Plasma amantadine concentrations in patients with Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Creatinine; Delirium; Female; Hallucinations; Humans; | 2009 |
Altered mental status in a transplant patient. Amantadine toxicity.
Topics: Adult; Amantadine; Confusion; Diabetes Complications; Diabetes Mellitus, Type 1; Female; Hallucinati | 2009 |
Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Hallucinations; Humans; Music; Parkinson Disease | 2010 |
An artist's view of drug-induced hallucinosis.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2003 |
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; | 2005 |
Features associated with the development of hallucinations in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Brain; Cholinergic Antagonists; Do | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
[A study on mental symptoms developing during the treatment of Parkinson's disease (author's transl)].
Topics: Aged; Amantadine; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Hypertension | 1980 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combination | 1997 |
Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation.
Topics: Accidental Falls; Adult; Akathisia, Drug-Induced; Amantadine; Brain Injuries; Bromocriptine; Dopamin | 1999 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; | 1975 |
Amantadine neurotoxicity in a pediatric patient with renal insufficiency.
Topics: Adolescent; Amantadine; Central Nervous System Diseases; Creatine; Female; Graft Rejection; Hallucin | 1991 |
Amantadine toxicity presenting with complex ventricular ectopy and hallucinations.
Topics: Adolescent; Amantadine; Arrhythmias, Cardiac; Charcoal; Drug Overdose; Electrocardiography; Emergenc | 1991 |
Acute psychosis after amantadine overdose.
Topics: Adult; Amantadine; Diagnosis, Differential; Diphenhydramine; Drug Synergism; Female; Hallucinations; | 1990 |
Visual hallucinations. The unwanted effect of patient compliance.
Topics: Aged; Amantadine; Female; Hallucinations; Humans; Patient Compliance; Vision Disorders | 1985 |
[Amantadine in the treatment of Parkinson's disease].
Topics: Amantadine; Drug Eruptions; Hallucinations; Humans; Parkinson Disease; Time Factors | 1972 |
L-dopa for parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Follow-Up Studies; Hallucinations; Hum | 1973 |
Coloured Lilliputian hallucinations with amantadine.
Topics: Aged; Amantadine; Female; Hallucinations; Humans; Male; Parkinson Disease; Tremor; Visual Pathways | 1973 |
[Amantadine treatment in parkinsonism].
Topics: Administration, Oral; Amantadine; Anxiety; Hallucinations; Humans; Parkinson Disease; Sleep Wake Dis | 1973 |
L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
Topics: Aged; Amantadine; Chlorides; Depression; Dihydroxyphenylalanine; Drug Hypersensitivity; Female; Foll | 1971 |